Sanofi - ADR (SNY): Price and Financial Metrics


Sanofi - ADR (SNY)

Today's Latest Price: $49.69 USD

0.05 (0.10%)

Updated Jan 22 6:55pm

Add SNY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SNY Stock Summary

  • With a market capitalization of $124,605,290,489, Sanofi has a greater market value than 98.24% of US stocks.
  • With a year-over-year growth in debt of 54.84%, Sanofi's debt growth rate surpasses 83.04% of about US stocks.
  • In terms of volatility of its share price, SNY is more volatile than merely 0.39% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sanofi are LIN, AZN, RTX, CAT, and IBM.
  • SNY's SEC filings can be seen here. And to visit Sanofi's official web site, go to www.sanofi.com.

SNY Stock Price Chart Interactive Chart >

Price chart for SNY

SNY Price/Volume Stats

Current price $49.69 52-week high $55.00
Prev. close $49.64 52-week low $37.62
Day low $49.36 Volume 3,099,100
Day high $50.02 Avg. volume 3,171,507
50-day MA $49.21 Dividend yield 2.35%
200-day MA $49.88 Market Cap 124.43B

Sanofi - ADR (SNY) Company Bio


Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.

SNY Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$49.69$58.27 17%

We started the process of determining a valid price forecast for Sanofi with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Sanofi ranked in the 55th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 17.83%. In terms of the factors that were most noteworthy in this DCF analysis for SNY, they are:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 69. Its equity weight surpasses that of only 19.54% of free cash flow generating stocks in the Healthcare sector.
  • Sanofi's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 6.21% of tickers in our DCF set.
  • SNY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than only 6.21% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%15%
1%16%
2%17%
3%18%
4%20%
5%21%

Want more companies with a valuation profile/forecast similar to that of Sanofi? See PRAH, UNH, REGN, CMD, and DXCM.


SNY Latest News Stream


Event/Time News Detail
Loading, please wait...

SNY Latest Social Stream


Loading social stream, please wait...

View Full SNY Social Stream

Latest SNY News From Around the Web

Below are the latest news stories about Sanofi that investors may wish to consider to help them evaluate SNY as an investment opportunity.

Bangladeshi drugmaker acquiring country's Sanofi subsidiary

A leading Bangladeshi drugmaker is acquiring a majority stake in French pharmaceutical giant Sanofi’s subsidiary in Bangladesh

ABC News | January 21, 2021

Diagnostic Specialty Antibodies Market with Pandemic Analysis, Growth Rate, New Trend Analysis Forecast To 2027 | Sanofi, Abbott Laboratories, Abcam, Bio-Rad Laboratories, Agilent Technologies

Antibodies are blood protein. Every specific antigen has a specific antibody manufactured by the body. They are generally called immunoglobulin and are usually in the shape of the Y structure. Upgrades in technology, especially in the field of genetic engineering

OpenPR | January 21, 2021

Biologics Market - AbbVie, Amgen, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Merck KGaA, Novartis, Pfizer, F. Hoffmann-La Roche Ltd, and Sanofi.

Coherent Market Insights has recently updated its massive report catalog by adding a fresh study titled "Global Biologics Market – Industry Analysis, Size, Share, Growth, Trends, & Forecast 2020 – 2027". This business intelligence study encapsulates vital details about the

OpenPR | January 21, 2021

Global Human Insulin Market Forecast Revised as COVID-19 Estimated to Hold a Huge Impact on Sales in 2021 | Sanofi (France), Eli Lilly and Company (U.S.),Biocon Ltd. (India),Julphar (U.A.E.),Ypsomed AG (Switzerland),Becton, Dickinson and Company (U.S.)

Latest Survey On Human Insulin Market: ‘Market Growth Insight’ has presented an updated research report on ‘The Global Human Insulin market’ which offers insights on key aspects and an overview of the fundamental verticals of the market. The Human Insulin report

OpenPR | January 21, 2021

Global Vaccine Market Advance Technology And New Innovations 2020 To 2027||Pfizer Inc, Glaxosmithkline plc, Merck Co., Inc, Sanofi, CSL Limited, Panacea Biotec Ltd., Novavax

The Vaccine statistical surveying report contains market experiences and investigation for Pharmaceutical industry which are sponsored up by SWOT examination. According to the expectations refered to in this report, the market will develop with a particular CAGR esteem in the

OpenPR | January 21, 2021

Read More 'SNY' Stories Here

SNY Price Returns

1-mo N/A
3-mo 4.83%
6-mo -5.96%
1-year 4.47%
3-year 22.86%
5-year 42.14%
YTD 2.26%
2020 -0.83%
2019 23.73%
2018 4.20%
2017 8.73%
2016 -2.52%

SNY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full SNY Dividend History

Continue Researching SNY

Want to see what other sources are saying about Sanofi's financials and stock price? Try the links below:

Sanofi (SNY) Stock Price | Nasdaq
Sanofi (SNY) Stock Quote, History and News - Yahoo Finance
Sanofi (SNY) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9285 seconds.